New Zealand - English - Medsafe (Medicines Safety Authority)

dentsply sirona (nz) limited - adrenaline acid tartrate 18.2 µg/ml equivalent to adrenaline 10 micrograms/ml; articaine hydrochloride 40 mg/ml - solution for injection - active: adrenaline acid tartrate 18.2 µg/ml equivalent to adrenaline 10 micrograms/ml articaine hydrochloride 40 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide sodium metabisulfite water for injection - indicated for local or regional anaesthesia for both simple and complex dental procedures in adults, adolescents and children 4 years of age and older. indicated only for dental procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - adrenaline (epinephrine) acid tartrate, quantity: 182 microgram/ml (equivalent: adrenaline (epinephrine), qty 100 microgram/ml) - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium metabisulfite; dilute hydrochloric acid; water for injections; sodium chloride; citric acid monohydrate - adrenaline 1:10,000 is used as an adjunct in the management of cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - adrenaline (epinephrine) acid tartrate, quantity: 182 microgram/ml (equivalent: adrenaline (epinephrine), qty 100 microgram/ml) - injection, solution - excipient ingredients: citric acid monohydrate; sodium metabisulfite; sodium chloride; sodium citrate dihydrate; water for injections; dilute hydrochloric acid - adrenaline 1:10,000 is used as an adjunct in the management of cardiac arrest.

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - benazepril hydrochloride 5 mg - benazepril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration). benazepril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are anuric. benazepril hydrochloride and hydrochlorothiazide tablets are also contraindicated in patients who are hypersensitive to benazepril, to any other ace inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. hypersensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. benazepril hydrochloride and hydrochlorothiazide tablets are also contraindicated in patients with a history of angioedema with or without previous ace inhibitor treatment. do not co-administer aliskiren with angiotensin receptor blockers, ace inhibitors, including benazepril hydrochloride and hydrochlorothiazide tablets in patients with diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - adrenaline (epinephrine) acid tartrate, quantity: 1.82 mg/ml (equivalent: adrenaline (epinephrine), qty 1 mg/ml) - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; hydrochloric acid; sodium hydroxide; water for injections - indications as at 27 june 2003: adrenaline 1:1,000 is the drug of choice in the emergency treatment of acute severe anaphylactic reactions due to insect bites, drugs and other allergens. it may also be used for the symptomatic relief of respiratory distress due to bronchospasm.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg in 1 ml - granisetron hydrochloride injection, usp is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (e.g. anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. teratogenic effects pregnancy category b reproduction  studies  have  been  performed  in  pregnant  rats  at  intravenous  doses  up  to  9 mg/kg/day (54 mg/m2 /day, 146 times the recommended human dose based on body surface area) and pregnant rabbits at intravenous doses up to 3 mg/kg/day (35.4 mg/m2 /day, 96 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to granisetron. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. benzyl alcohol may cross the placenta. granisetron hydrochloride injection 1 mg/ml is preserved with benzyl alcohol and should be used in pregnancy only if the benefit outweighs the potential risk. it is not known whether granisetron is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when granisetron hydrochloride injection is administered to a nursing woman. benzyl alcohol, a component of granisetron hydrochloride injection 1 mg/ml, has been associated with serious adverse reactions and death, particularly in neonates [see warnings and precautions (5.4)] . chemotherapy-induced nausea and vomiting [see dosage and administration (2)] for use in chemotherapy-induced nausea and vomiting in pediatric patients 2 to 16 years of age. safety and effectiveness in pediatric patients under 2 years of age have not been established. postoperative nausea and vomiting safety and efficacy have not been established in pediatric patients for the prevention of postoperative nausea and vomiting (ponv). granisetron has been evaluated in a pediatric patient clinical trial for use in the prevention of ponv. due to the lack of efficacy and the qt prolongation observed in this trial, use of granisetron for the prevention of ponv in children is not recommended. the trial was a prospective, multicenter, randomized, double-blind, parallel-group trial that evaluated 157 children aged 2 to 16 years who were undergoing elective surgery for tonsillectomy or adenotonsillectomy. the purpose of the trial was to assess two dose levels (20 mcg/kg and 40 mcg/kg) of intravenous granisetron in the prevention of ponv. there was no active comparator or placebo. the primary endpoint was total control of nausea and vomiting (defined as no nausea, vomiting/retching, or use of rescue medication) in the 24 hours following surgery. efficacy was not established due to lack of a dose response. the trial also included standard 12 lead ecgs performed pre-dose and after the induction of anesthesia. ecgs were repeated at the end of surgery after the administration of granisetron and just prior to reversal of anesthesia. qt prolongation was seen at both dose levels. five patients in this trial experienced an increase of ≥ 60 msec in qtcf. in addition, there were two patients whose qtcf was ≥ 500 msec. interpretation of the qtcf prolongation was confounded by multiple factors, including the use of concomitant medication and the lack of either a placebo or active control. a thorough qt trial in adults has not been performed. other adverse events that occurred in the study included: vomiting (5 to 8%), post-procedural hemorrhage (3 to 5%), and dehydration (0 to 5%). pediatric patients under 2 years of age have not been studied. during chemotherapy clinical trials, 713 patients 65 years of age or older received granisetron hydrochloride injection. the safety and effectiveness were similar in patients of various ages.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adrenaline 1mg;   - solution for injection - 1mg/10ml - active: adrenaline 1mg   excipient: hydrochloric acid sodium chloride sodium hydroxide sodium metabisulfite tartaric acid water for injection - adrenaline 1:10,000. an adjunct in the management of cardiac arrest.

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratoire aguettant - adrenaline tartrate - solution for injection in pre-filled syringe - 1 milligram/10 millilitres - adrenergic and dopaminergic agents; epinephrine

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - noradrenaline acid tartrate 2 mg/ml equivalent to 1 mg/ml noradrenaline base;   - concentrate for injection - 1 mg/ml - active: noradrenaline acid tartrate 2 mg/ml equivalent to 1 mg/ml noradrenaline base   excipient: nitrogen sodium chloride water for injection - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusions and drug reactions). as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate, quantity: 2 mg/ml (equivalent: noradrenaline (norepinephrine), qty 1 mg/ml) - injection, concentrated - excipient ingredients: sodium chloride; water for injections - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions). as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.